New drugs targeting Th2 lymphocytes in asthma

Journal of Occupational Medicine and Toxicology

Volumn 3, Issue SUPPL. 1, 2008, Pages

  Caramori, Gaetano ^a   Groneberg, David ^b   Ito, Kazuhiro ^c   Casolari, Paolo ^a   Adcock, Ian M ^c   Papi, Alberto ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

EID: 44949095421     PISSN: None     EISSN: 17456673     Source Type: Journal    
DOI: 10.1186/1745-6673-3-S1-S6     Document Type: Conference Paper

References (326)

1. The costs of asthma. PJ Barnes B Jonsson JB Klim, Eur Respir J 1996 9 4 636 642
2. Evaluation and management of severe asthma. M Gaga E Zervas S Grivas M Castro P Chanez, Curr Med Chem 2007 14 9 1049 1059
3. Global Initiative for Asthma: Global strategy for Asthma Management and Prevention. NHLBI/WHO Workshop report 2002. NIH Publication No 02-3659: 1-200. Last update 2006. Freely available online at http://www.ginasthma.com (accessibility verified 15 July 2007).
4. Omalizumab for asthma. RC Strunk GR Bloomberg, N Engl J Med 2006 354 25 2689 2695
5. Does anti-IgE therapy help in asthma? Efficacy and controversies. PC Avila, Annu Rev Med 2007 58 185 203
6. Murine models of asthma. JC Kips GP Anderson JJ Fredberg U Herz MD Inman M Jordana DM Kemeny J Lotvall RA Pauwels CG Plopper D Schmidt PJ Sterk AJ Van Oosterhout BB Vargaftig KF Chung, Eur Respir J 2003 22 2 374 382
7. How do corticosteroids work in asthma? PJ Barnes IM Adcock, Ann Intern Med 2003 139 5 Pt 1 359 370
8. Pharmacology of airway inflammation in asthma and COPD. G Caramori I Adcock, Pulm Pharmacol Ther 2003 16 5 247 277
9. Is there a difference between chronic airway inflammation in chronic severe asthma and chronic obstructive pulmonary disease? G Caramori A Pandit A Papi, Curr Opin Allergy Clin Immunol 2005 5 1 77 83
10. Glucocorticoid-resistant asthma. TK Loke AR Sousa CJ Corrigan TH Lee, Curr Allergy Asthma Rep 2002 2 2 144 150
11. Corticosteroid-insensitive asthma: molecular mechanisms. IM Adcock J Lane, J Endocrinol 2003 178 3 347 355
12. Inflammatory mediators of asthma: an update. PJ Barnes KF Chung CP Page, Pharmacol Rev 1998 50 4 515 596
13. Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids. H Miyaura M Itawa, J Immunol 2002 168 3 1087 1094
14. Distinct leucocyte redistribution after glucocorticoid treatment among difficult-to-treat asthmatic patients. C Karagiannidis B Ruckert G Hense G Willer G Menz K Blaser CB Schmidt-Weber, Scand J Immunol 2005 61 2 187 196
15. Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists. EJ Peek DF Richards A Faith P Lavender TH Lee CJ Corrigan CM Hawrylowicz, Am J Respir Cell Mol Biol 2005 33 1 105 111
16. Repression of interleukin-5 transcription by the glucocorticoid receptor targets GATA3 signaling and involves histone deacetylase recruitment. YK Jee J Gilour A Kelly H Bowen D Richards C Soh P Smith C Hawrylowicz D Cousins T Lee P Lavender, J Biol Chem 2005 280 24 23243 23250
17. Glucocorticoids inhibit proliferation and interleukin-4 and interleukin-5 secretion by aeroallergen-specific T-helper type 2 cell lines. IC Crocker MK Church S Newton RG Townley, Ann Allergy Asthma Immunol 1998 80 6 509 516
18. The topical glucocorticoids beclomethasone dipropionate and fluticasone propionate inhibit human T-cell allergen-induced production of IL-5, IL-3 and GM-CSF mRNA and protein. N Powell SJ Till AB Kay CJ Corrigan, Clin Exp Allergy 2001 31 1 69 76
19. Differential control of TH1 versus TH2 cell responses by the combination of low-dose steroids with beta2-adrenergic agonists. E Goleva A Dunlap DY Leung, J Allergy Clin Immunol 2004 114 1 183 191
20. In vitro effects of fluticasone propionate on IL-13 production by mitogen-stimulated lymphocytes. G Di Lorenzo ML Pacor ME Pellitteri S Gangemi P Di Blasi G Candore A Colombo D Lio C Caruso, Mediators Inflamm 2002 11 3 187 190
21. Fluticasone induces apoptosis in peripheral T-lymphocytes: a comparison between asthmatic and normal subjects. M Melis L Siena E Pace M giomarkaj M Profita A Piazzoli M Todaro G Stassi G Bonsignore AM Vignola, Eur Respir J 2002 19 2 257 266
22. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. E Pace R Gagliardo M Melis S La Grutta L Siena G Monsignore M Giomarkaj J Bousquet AM Vignola, J Allergy Clin Immunol 2004 114 5 1216 1223
23. Theophylline: new perspectives for an old drug. PJ Barnes, Am J Respir Crit Care Med 2003 167 6 813 818
24. Theophylline in chronic obstructive pulmonary disease: new horizons. PJ Barnes, Proc Am Thorac Soc 2005 2 4 334 339 discussion 340-341
25. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. P Sullivan S Bekir Z Jaffar C Page P Jeffery J Costello, Lancet 1994 343 8904 1006 1008 Erratum in: Lancet 1994, 343(8911): 1512
26. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. ZH Jaffar P Sullivan C Page J Costello, Eur Respir J 1996 9 3 456 462
27. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. R Djukanovic JP Finnerty C Lee S Wilson J Madden ST Holgate, Eur Respir J 1995 8 5 831 833
28. Effects of theophylline on inflammatory cells and cytokines in asthmatic subjects: a placebo-controlled parallel group study. JP Finnerty C Lee S Wilson J Madden R Djukanovic ST Holgate, Eur Respir J 1996 9 8 1672 1677
29. Effects of theophylline on CD4+ T lymphocyte, interleukin-5, and interferon gamma in induced sputum of asthmatic subjects. HX Nie J Yang SP Hu XJ Wu, Acta Pharmacol Sin 2002 23 3 267 272
30. Immunomodulation by theophylline in asthma: demonstration by withdrawal of therapy. J Kidney M Dominguez PM Taylor M Rose KF Chung PJ Barnes, Am J Respir Crit Care Med 1995 151 6 1907 1914
31. Phosphodiesterase and cyclic adenosine monophosphate-dependent inhibition of T-lymphocyte chemotaxis. R Hidi S Timmermans E Liu C Schudt G Dent ST Holgate R Djukanovic, Eur Respir J 2000 15 2 342 349
32. Theophylline and the immune response: in vitro and in vivo effects. A Scordamaglia G Ciprandi S Ruffoni M Caria F Paolieri D Venuti GW Canonica, Clin Immunol Immunopathol 1988 48 2 238 246
33. Effects of theophylline, dexamethasone and salbutamol on cytokine gene expression in human peripheral blood CD4+ T-cells. DK Choy F Ko ST Li LS Ip R Leung D Hui KN Lai CK Lai, Eur Respir J 1999 14 5 1106 1112
34. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells. IC Crocker RG Townley MM Khan, Immunopharmacology 1996 31 2-3 223 235
35. Pulmonary function changes and immunomodulation of Th 2 cytokine expression induced by aminophylline after sensitization and allergen challenge in brown Norway rats. CC Lin CY Lin SF Liaw A Chen, Ann Allergy Asthma Immunol 2002 88 2 215 222
36. Antileukotriene therapy. Future directions. ST Holgate AP Sampson, Am J Respir Crit Care Med 2000 161 2 Pt 2) s147 153
37. Effects of ONO-1078 (pranlukast) on cytokine production in peripheral blood mononuclear cells of patients with bronchial asthma. Y Tohda H Nakahara H Kubo R Haraguchi M Fukuoka S Nakajima, Clin Exp Allergy 1999 29 11 1532 1536
38. Effects of anti-inflammatory therapies on recurrent and low-grade respiratory syncytial virus infections in a murine model of asthma. H Matsuse Y Kondo I Machida T Kawano S Saeki S Tomari Y Obase C Fukushima Y Mizuta S Kohno, Ann Allergy Asthma Immunol 2006 97 1 55 60
39. Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. AY Wu SC Chik AW Chan Z Li KW Tsang W Li, Clin Exp Allergy 2003 33 3 359 366
40. Interleukin-2-induced increased airway responsiveness and lung Th2 cytokine expression occur after antigen challenge through the leukotriene pathway. S Nag B Lamkhioued PM Renzi, Am J Respir Crit Care Med 2002 165 11 1540 1545
41. Nasal cytokine modulation by montelukast in allergic children: a pilot study. G Ciprandi F Frati F Marcucci L Sensi MA Tosca M Milanese V Ricca, Allerg Immunol (Paris) 2003 35 8 295 299
42. Activated T helper 1 and T helper 2 cells differentially express the beta-2-adrenergic receptor: a mechanism for selective modulation of T helper 1 cell cytokine production. DS Ramer-Quinn RA Baker VM Sanders, J Immunol 1997 159 10 4857 4867
43. Differential expression of the beta2-adrenergic receptor by Th1 and Th2 clones: implications for cytokine production and B cell help. VM Sanders RA Baker DS Ramer-Quinn DJ Kasprowicz BA Fuchs NE Street, J Immunol 1997 158 9 4200 4210
44. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. P Panina-Bordignon D Mazzeo PD Lucia D D'Ambrosio R Lang L Fabbri C Self F Sinigaglia, J Clin Invest 1997 100 6 1513 1519
45. Effects of beta2 adrenoceptor agonists on T-cell subpopulations. E Holen S Elsayed, APMIS 1998 106 9 849 857
46. The effects of regular inhaled formoterol and budesonide on preformed Th-2 cytokines in mild asthmatics. A Wallin T Sandstrom GD Cioppa S Holgate S Wilson, Respir Med 2002 96 12 1021 1025
47. Pharmacologic modulation of Th1 and Th2 cell subsets by nedocromil sodium. JR Farrar DK Rainey AA Norris, Int Arch Allergy Immunol 1995 107 1-3 414 415
48. Methotrexate as a steroid sparing agent for asthma in adults. H Davies L Olson P Gibson, Cochrane Database Syst Rev 2000 2 CD000391
49. The role of T lymphocytes in asthma. AB Kay, Chem Immunol Allergy 2006 91 59 75
50. Cyclosporin as an oral corticosteroid sparing agent in stable asthma. DJ Evans P Cullinan DM Geddes, Cochrane Database Syst Rev 2001 2 CD002993
51. New therapies for asthma. PJ Barnes, Trends Mol Med 2006 12 11 515 520
52. Targeting Th2 cells in asthmatic patients. G Caramori K Ito IM Adcock, Curr Drug Targets Inflamm Allergy 2004 3 3 243 255
53. Efficacy and safety of roflumilast in the treatment of asthma. ED Bateman L Izquierdo U Harnest P Hofbauer P Magyar C Schmid-Wirlitsch S Leichtl D Bredenboker, Ann Allergy Asthma Immunol 2006 96 5 679 686
54. Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects. LJ Landells CM Szilagy NA Jones KH Banner JM Allen A Doherty BJ O'Connor D Spina CP Page, Br J Pharmacol 2001 133 5 722 729
55. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. DM Essayan A Kagey-Sobotka LM Lichtenstein SK Huang, J Pharmacol Exp Ther 1997 282 1 505 512
56. Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones. DM Essayan A Kagey-Sobotka LM Lichtenstein SK Huang, Biochem Pharmacol 1997 53 7 1055 1060
57. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. B Bielekova A Lincoln H McFarland R Martin, J Immunol 2000 164 2 1117 1124
58. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents. P Marcoz AF Prigent M Lagarde G Nemoz, Mol Pharmacol 1993 44 5 1027 1035
59. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. N Sommer R Martin HF McFarland L Quigley B Cannella CS Raine DE Scott PA Loschmann MK Racke, J Neuroimmunol 1997 79 1 54 61
60. Chemokines and asthma. IM Adcock G Caramori, Curr Drug Targets Inflamm Allergy 2004 3 3 257 261
61. The many roles of chemokines and chemokine receptors in inflammation. IF Charo RM Ransohoff, N Engl J Med 2006 354 6 610 621
62. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. MJ Leckie A ten Brinke J Khan Z Diamant BJ O'Connor CM Walls AK Mathur HC Cowley KF Chung R Djukanovic TT Hansel ST Holgate PJ Sterk PJ Barnes, Lancet 2000 356 9248 2144 2148
63. Eotaxin receptor (CCR3) antagonism in asthma and allergic disease. EM Erin TJ Williams PJ Barnes TT Hansel, Curr Drug Targets Inflamm Allergy 2002 1 2 201 214
64. N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists. DG Batt GC Houghton J Roderick JB Santella 3rd DA Wacker PK Welch YI Orlovsky EA Wadman JM Trzaskos P Davies CP Decicco PH Carter, Bioorg Med Chem Lett 2005 15 3 787 791
65. Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl- piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists. GV De Lucca UT Kim C Johnson BJ Vargo PK Welch M Covington P Davies KA Solomon RC Newton GL Trainor CP Decicco SS Ko, J Med Chem 2002 45 17 3794 3804
66. Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency. GV De Lucca UT Kim BJ Vargo JV Duncia JB Santella 3rd DS Gardner C Zheng A Liauw Z Wang G Emmett DA Wacker PK Welch M Covington NC Stowell EA Wadman AM Das P Davies S Yeleswaram DM Graden KA Solomon RC Newton GL Trainor CP Decicco SS Ko, J Med Chem 2005 48 6 2194 2211
67. Recent developments in CCR3 antagonists. GV De Lucca, Curr Opin Drug Discov Devel 2006 9 4 516 524
68. Ono SJT: A specific CCR3 chemokine receptor antagonist inhibits both early and late phase allergic inflammation in the conjunctiva. T Nakamura M Ohbayashi M Toda DA Hall CM Horgan, Immunol Res 2005 33 3 213 221
69. CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity. JR Pruitt DG Batt DA Wacker LL Bostrom SK Booker E McLaughlin GC Houghton JG Varnes DD Christ M Covington AM Das P Davies D Graden I Kariv Y Orlovsky NC Stowell KG Vaddi EA Wadman PK Welch S Yeleswaram KA Solomon RC Newton CP Decicco PH Carter SS Ko, Bioorg Med Chem Lett 2007 17 11 2992 2997
70. In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031. K Suzuki T Morokata K Morihira I Sato S Takizawa M Kaneko K Takahashi Y Shimizu, Biochem Biophys Res Commun 2006 339 4 1217 1223
71. Effects of a low-molecular-weight CCR-3 antagonist on chronic experimental asthma. M Wegmann R Goggel S Sel S Sel KJ Erb F Kalkbrenner H Renz H Garn, Am J Respir Cell Mol Biol 2007 36 1 61 67
72. A dual antagonist for chemokine CCR3 receptor and histamine H(1) receptor. K Suzuki T Morokata K Morihira I Sato S Takizawa M Kaneko K Takahashi Y Shimizu, Eur J Pharmacol 2007 563 1-3 224 232
73. Selective inhibition of eosinophil influx into the lung by small molecule CC chemokine receptor 3 antagonists in mouse models of allergic inflammation. AM Das KG Vaddi KA Solomon C Krauthauser X Jiang KW McIntyre XX Yang E Wadman P Welch M Covington D Graden K Yeleswaram JM Trzaskos RC Newton S Mandlekar SS Ko PH Carter P Davies, J Pharmacol Exp Ther 2006 318 1 411 417
74. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. AD Fryer LH Stein Z Nie DE Curtis CM Evans ST Hodgson PJ Jose KE Belmonte E Fitch DB Jacoby, J Clin Invest 2006 116 1 228 236
75. n-Nonanoyl-CC chemokine ligand 14, a potent CC chemokine ligand 14 analogue that prevents the recruitment of eosinophils in allergic airway inflammation. U Forssmann I Hartung R Balder B Fuchs SE Escher N Spodsberg Y Dulkys M Walden A Heitland A Braun WG Forssmann J Elsner, J Immunol 2004 173 5 3456 3466
76. The allergy-associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY-CCL11. J Manns S Rieder S Escher B Eilers WG Forssmann J Elsner U Forssmann, Allergy 2007 62 1 17 24
77. Reversal of airway inflammation and remodeling in asthma by a bispecific antibody fragment linking CCR3 to CD300a. A Munitz I Bachelet F Levi-chaffer, J Allergy Clin Immunol 2006 118 5 1082 1089
78. CCR4 blockade does not inhibit allergic airways inflammation. DM Conroy LA Jopling CM Lloyd MR Hodge DP Andrew TJ Williams JE Pease I Sabroe, J Leukoc Biol 2003 74 4 558 563
79. Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists. S Allen B Newhouse AS Anderson B Fauber A Allen D Chantry C Eberhardt J Odino LE Burgess, Bioorg Med Chem Lett 2004 14 7 1619 1624
80. Racemic and chiral lactams as potent, selective and functionally active CCR4 antagonists. B Newhouse S Allen B Fauber AS Anderson CT Eary JD Hansen J Schiro JJ Gaudino E Laird D Chantry C Eberhardt LE Burgess, Bioorg Med Chem Lett 2004 14 22 5537 5542
81. Identification of chemokine receptor CCR4 antagonist. AV Purandare A Gao H Wan JE Somerville C Burke C Seachord W Vaccaro J Wityak MA Poss, Bioorg Med Chem Lett 2005 15 10 2669 2672
82. Optimization of CCR4 antagonists: side-chain exploration. AV Purandare H Wan A Gao JE Somerville C Burke W Vaccaro X Yang KW McIntyre MA Poss, Bioorg Med Chem Lett 2006 16 1 204 207
83. Antagonists of CCR4 as immunomodulatory agents. AV Purandare JE Somerville, Curr Top Med Chem 2006 6 13 1335 1344
84. Core exploration in optimization of chemokine receptor CCR4 antagonists. AV Purandare H Wan JE Somerville C Burke W Vaccaro X Yang KW McIntyre MA Poss, Bioorg Med Chem Lett 2007 17 3 679 682
85. CCR8 is not essential for the development of inflammation in a mouse model of allergic airway disease. CD Chung F Kuo J Kumer AS Motani CE Lawrence WR Henderson Jr C Venkataraman, J Immunol 2003 170 1 581 587
86. Absence of CCR8 does not impair the response to ovalbumin-induced allergic airway disease. I Goya R Villares A Zaballos J Gutierrez L Kremer JA Gonzalo R Varona L Carramolino A Serrano P Pallares LM Criado R Kolbeck M Torres AJ Coyle JC Gutierrez-Ramos C Martinez-A G Marquez, J Immunol 2003 170 4 2138 2146
87. Structure/function relationships of CCR8 agonists and antagonists. Amino-terminal extension of CCL1 by a single amino acid generates a partial agonist. JM Fox P Najarro GL Smith S Struyf P Proost JE Pease, J Biol Chem 2006 281 48 36652 36661
88. Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8). S Ghosh A Elder J Guo U Mani M Patane K Carson Q Ye R Bennett S Chi T Jenkins B Guan R Kolbeck S Smith C Zhang G LaRosa B Jaffee H Yang P Eddy C Lu V Uttamsingh R Horlick G Harriman D Flynn, J Med Chem 2006 49 9 2669 2672
89. In vitro selection of RNA aptamers that block CCL1 chemokine function. ML Marro DA Daniels DP Andrews TD Chapman KL Gearing, Biochem Biophys Res Commun 2006 349 1 270 276
90. CCR8 antagonists. P Norman, Exp Opin Ther Patents 2007 17 4 465 469
91. An orally bioavailable small molecule antagonist of CRTH2, ramatroban (BAY u3405), inhibits prostaglandin D2-induced eosinophil migration in vitro. H Sugimoto M Shichijo T Iino Y Manabe A Watanabe M Shimazaki F Gantner KB Bacon, J Pharmacol Exp Ther 2003 305 1 347 352
92. Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation. L Uller JM Mathiesen L Alenmyr M Korsgren T Ulven T Hogberg G Andersson CG Persson E Kostenis, Respir Res 2007 8 16
93. Indole-3-acetic acid antagonists of the prostaglandin D2 receptor CRTH2. RE Armer MR Ashton EA Boyd CJ Brennan FA Brookfield L Gazi SL Gyles PA Hay MG Hunter D Middlemiss M Whittaker L Xue R Pettipher, J Med Chem 2005 48 20 6174 6177
94. Discovery of potent CRTh2 (DP2) receptor antagonists. TN Birkinshaw SJ Teague C Beech RV Bonnert S Hill A Patel S Reakes H Sanganee IG Dougall TT Phillips S Salter J Schmidt EC Arrowsmith JJ Carrillo FM Bell SW Paine R Weaver, Bioorg Med Chem Lett 2006 16 16 4287 4290
95. Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview. TW Ly KB Bacon, Expert Opin Investig Drugs 2005 14 7 769 773
96. Identification of indole derivatives exclusively interfering with a G protein-independent signaling pathway of the prostaglandin D2 receptor CRTH2. JM Mathiesen T Ulven L Martini LO Gerlach A Heinemann E Kostenis, Mol Pharmacol 2005 68 2 393 402
97. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. R Pettipher TT Hansel R Armer, Nat Rev Drug Discov 2007 6 4 313 325
98. Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits. T Ulven JM Receveur M Grimstrup O Rist TM Frimurer LO Gerlach JM Mathiesen E Kostenis L Uller T Hogberg, J Med Chem 2006 49 23 6638 6641
99. Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. T Ulven E Kostenis, Curr Top Med Chem 2006 6 13 1427 1444
100. Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues Is not mediated through CCR3. Y Chvatchko AE Proudfoot R Buser P Juillard S Alouani M Kosco-Vilbois AJ Coyle RJ Nibbs G Graham RE Offord TN Wells, J Immunol 2003 171 10 5498 5506
101. Transduction of multiple effects of sphingosine 1-phosphate (S1P) on T cell functions by the S1P1 G protein-coupled receptor. G Dorsam MH Graeler C Seroogy Y Kong JK Voice EJ Goetzl, J Immunol 2003 171 7 3500 3507
102. Inhibition of Th1- and th2-mediated airway inflammation by the sphingosine 1-phosphate receptor agonist FTY720. E Sawicka C Zuany-Amorim C Manlius A Trifilieff V Brinkmann DM Kemeny C Walker, J Immunol 2003 171 11 6206 6214
103. Local application of FTY720 to the lung abrogates experimental asthma by altering dendritic cell function. M Idzko H Hammad M van Nimwegen M Kool T Muller T Soullie MA Willart D Hijdra HC Hoogsteden BN Lambrecht, J Clin Invest 2006 116 11 2935 2944
104. YM-58483 a selective CRAC channel inhibitor, prevents antigen-induced airway eosinophilia and late phase asthmatic responses via Th2 cytokine inhibition in animal models. T Yoshino J Ishikawa K Ohga T Morokata R Takezawa H Morio Y Okada K Honda T Yamada, Eur J Pharmacol 2007 560 2-3 225 233
105. Transcription factors in airway diseases. PJ Barnes, Lab Invest 2006 86 9 867 872
106. Transcription factors in asthma and COPD. G Caramori K Ito IM Adcock, IDrugs 2004 7 8 764 770
107. Kinase inhibitors and airway inflammation. IM Adcock KF Chung G Caramori K Ito, Eur J Pharmacol 2006 533 1-3 118 132
108. Anti-inflammatory inhibitors of IkappaB kinase in asthma and COPD. G Caramori IM Adcock K Ito, Curr Opin Investig Drugs 2004 5 11 1141 1147
109. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. S Fichtner-Feigl IJ Fuss JC Preiss W Strober A Kitani, J Clin Invest 2005 115 11 3057 3071
110. Chemogenomic identification of Ref-1/AP-1 as a therapeutic target for asthma. C Nguyen JL Teo A Matsuda M Eguchi EY Chi WR Henderson Jr M Kahn, Proc Natl Acad Sci USA 2003 100 3 1169 1173
111. Treatment of experimental asthma by decoy-mediated local inhibition of activator protein-1. C Desmet P Gosset E Henry V Garze P Faisca N Vos F Jaspar D Melotte B Lambrecht D Desmecht B Pajak M Moser P Lekeux F Bureau, Am J Respir Crit Care Med 2005 172 6 671 678
112. Increased messenger RNA expression of c-maf and GATA-3 after segmental allergen challenge in allergic asthmatics. VJ Erpenbeck JM Hohlfeld M Discher H Krentel A Hagenberg A Braun N Krug, Chest 2003 123 suppl 3 370S 371S
113. Regulation of GATA-3, c-maf and T-bet mRNA expression in bronchoalveolar lavage cells and bronchial biopsies after segmental allergen challenge. VJ Erpenbeck A Hagenberg H Krentel M Discher A Braun JM Hohlfeld N Krug, Int Arch Allergy Immunol 2006 139 4 306 316
114. Transcription factors T-bet and GATA-3 regulate development of airway remodeling. T Kiwamoto Y Ishii Y Morishima K Yoh A Maeda K Ishizaki T Iizuka AE Hegab Y Matsuno S Homma A Nomura T Sakamoto S Takahashi K Sekizawa, Am J Respir Crit Care Med 2006 174 2 142 151
115. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. S Finotto GT De Sanctis HA Lehr U Herz M Buerke M Schipp B Bartsch R Atreya E Schmitt PR Galle H Renz MF Neurath, J Exp Med 2001 193 11 1247 1260
116. STAT1 in peripheral tissue differentially regulates homing of antigen-specific Th1 and Th2 cells. Z Mikhak CM Fleming BD Medoff SY Thomas AM Tager GS Campanella AD Luster, J Immunol 2006 176 8 4959 4967
117. Differential expression of IL-10 receptor by epithelial cells and alveolar macrophages. S Lim G Caramori K Tomita E Jazrawi T Oates KF Chung PJ Barnes IM Adcock, Allergy 2004 59 5 505 514
118. Constitutive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma. D Sampath M Castro DC Look MJ Holtzman, J Clin Invest 1999 103 9 1353 1361
119. Inhibition of signal transducer and activator of transcription 1 attenuates allergen-induced airway inflammation and hyperreactivity. D Quarcoo S Weixler D Groneberg R Joachim B Ahrens AH Wagner M Hecker E Hamelmann, J Allergy Clin Immunol 2004 114 2 288 295
120. Signal transducer and activator of transcription 6 controls chemokine production and T helper cell type 2 cell trafficking in allergic pulmonary inflammation. A Mathew JA MacLean E DeHaan AM Tager FH Green AD Luster, J Exp Med 2001 193 9 1087 1096
121. Interleukin-13 in asthma pathogenesis. M Wills-Karp, Immunol Rev 2004 202 175 190
122. Th2 cytokine-associated transcription factors in atopic and nonatopic asthma: evidence for differential signal transducer and activator of transcription 6 expression. P Christodoulopoulos L Cameron Y Nakamura C Lemière S Muro M Dugas LP Boulet M Laviolette R Olivenstein Q Hamid, J Allergy Clin Immunol 2001 107 4 586 591
123. In vivo expression of signal transducer and activator of transcription factor 6 (STAT6) in nasal mucosa from atopic allergic rhinitis: effect of topical corticosteroids. O Ghaffar P Christodoulopoulos B Lamkhioued E Wright D Ihaku Y Nakamura S Frenkiel Q Hamid, Clin Exp Allergy 2000 30 1 86 93
124. Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium. RE Mullings SJ Wilson SM Puddicombe JL Lordan F Bucchieri R Djukanovic PH Howarth S Harper ST Holgate DE Davies, J Allergy Clin Immunol 2001 108 5 832 838
125. STAT6 expression in T-cells subsets, alveolar macrophages and bronchial biopsies from normal and asthmatic subjects. G Caramori S Lim K Tomita K Ito T Oates K Chung PJ Barnes IM Adcock, Eur Respir J 2000 16 suppl 31 162s abstract P1188
126. Signaling pathways regulating interleukin-13-stimulated chemokine release from airway smooth muscle. Q Peng T Matsuda SJ Hirst, Am J Respir Crit Care Med 2004 169 5 596 603
127. Niflumic acid suppresses interleukin-13-induced asthma phenotypes. T Nakano H Inoue S Fukuyama K Matsumoto M Matsumura M Tsuda T Matsumoto H Aizawa Y Nakanishi, Am J Respir Crit Care Med 2006 173 11 1216 1221
128. The adipocyte fatty acid-binding protein aP2 is required in allergic airway inflammation. BO Shum CR Mackay CZ Gorgun MJ Frost RK Kumar GS Hotamisligil MS Rolph, J Clin Invest 2006 116 8 2183 2192
129. The transcription factor c-Maf controls the production of IL-4 but not other Th2 cytokine. JI Kim IC Ho MJ Grusby LH Glimcher, Immunity 1999 10 6 745 751
130. The cell type-specific expression of the murine IL-13 gene is regulated by GATA-3. H Kishikawa J Sun A Choi SC Miaw IC Ho, J Immunol 2001 167 8 4414 4420
131. Transcriptional regulation of th2 differentiation by inducible costimulator. RI Nurieva J Duong H Kishikawa U Dianzani JM Rojo I Ho RA Flavell C Dong, Immunity 2003 18 6 801 811
132. An IL-4-independent and CD25-mediated function of c-maf in promoting the production of Th2 cytokines. ES Hwang IA White IC Ho, Proc Natl Acad Sci USA 2002 99 20 13026 13030
133. c-maf promotes T helper cell type 2 (Th2) and attenuates Th1 differentiation by both interleukin 4-dependent and -independent mechanisms. IC Ho D Lo LH Glimcher, J Exp Med 1998 188 10 1859 1866
134. T helper type 2 cytokine receptors and associated transcription factors GATA-3, c-MAF, and signal transducer and activator of transcription factor-6 in induced sputum of atopic asthmatic patients. R Taha Q Hamid L Cameron R Olivenstein, Chest 2003 123 6 2074 2082
135. NFAT: ubiquitous regulator of cell differentiation and adaptation. V Horsley GK Pavlath, J Cell Biol 2002 156 5 771 774
136. Human eosinophils constitutively express nuclear factor of activated T cells p and c. MC Seminario J Guo BS Bochner LA Beck SN Georas, J Allergy Clin Immunol 2001 107 1 143 152
137. NFAT signaling: choreographing the social lives of cells. GR Crabtree EN Olson, Cell 2002 109 suppl S67 79
138. Transcriptional regulation by calcium, calcineurin, and NFAT. PG Hogan L Chen J Nardone A Rao, Genes Dev 2003 17 18 2205 2232
139. Transcriptional control of the IL-5 gene by human helper T cells: IL-5 synthesis is regulated independently from IL-2 or IL-4 synthesis. A Mori O Kaminuma T Mikami S Inoue Y Okumura K Akiyama H Okudaira, J Allergy Clin Immunol 1999 103 5 Pt 2 S429 436
140. Transcriptional regulation of the IL-5 gene in peripheral T cells of asthmatic patients. K Ogawa O Kaminuma H Okudaira H Kikkawa K Ikezawa N Sakurai A Mori, Clin Exp Immunol 2002 130 3 475 483
141. Preferential activation of nuclear factor of activated T cells c correlates with mouse strain susceptibility to allergic responses and interleukin-4 gene expression. JC Keen L Sholl M Wills-Karp SN Georas, Am J Respir Cell Mol Biol 2001 24 1 58 65
142. Induction of NFATc2 expression by interleukin 6 promotes T helper type 2 differentiation. S Diehl CW Chow L Weiss A Palmetshofer T Twardzik L Rounds E Serfling RJ Davis J Anguita M Rincon, J Exp Med 2002 196 1 39 49
143. Hyperproliferation and dysregulation of IL-4 expression in NF-Atp-deficient mice. MR Hodge AM Ranger F Charles de la Brousse T Hoey MJ Grusby LH Glimcher, Immunity 1996 4 4 397 405
144. Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Rengarajan KA Mowen KD McBride ED Smith H Singh LH Glimcher, J Exp Med 2002 195 8 1003 1012
145. NFATc2 and NFATc3 regulate T(H)2 differentiation and modulate TCR-responsiveness of naive T(H)cells. J Rengarajan B Tang LH Glimcher, Nat Immunol 2002 3 1 48 54
146. Silencer activity of NFATc2 in the interleukin-12 receptor beta 2 proximal promoter in human T helper cells. JG van Rietschoten HH Smits D van de Wetering R Westland CL Verweij MT den Hartog EA Wierenga, J Biol Chem 2001 276 37 34509 34516
147. An enhanced immune response in mice lacking the transcription factor NFAT1. S Xanthoudakis JP Viola KT Shaw C Luo JD Wallace PT Bozza DC Luk T Curran A Rao, Science 1996 272 5263 892 895
148. Role of NFATx (NFAT4/NFATc3) in expression of immunoregulatory genes in murine peripheral CD4+ T cells. J Chen Y Amasaki Y Kamogawa M Nagoya N Arai K Arai S Miyatake, J Immunol 2003 170 6 3109 3117
149. Inhibitory function of two NFAT family members in lymphoid homeostasis and Th2 development. AM Ranger M Oukka J Rengarajan LH Glimcher, Immunity 1998 9 5 627 635
150. TH1 and TH2 cytokine inhibition by 3,5-bis(trifluoromethyl)pyrazoles, a novel class of immunomodulators. Y Chen ML Smith GX Chiou S Ballaron MP Sheets E Gubbins U Warrior J Wilkins C Surowy M Nakane GW Carter JM Trevillyan K Mollison SW Djuric, Cell Immunol 2002 220 2 134 142
151. 3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator. SW Djuric NY BaMaung A Basha H Liu JR Luly DJ Madar RJ Sciotti NP Tu FL Wagenaar PE Wiedeman X Zhou S Ballaron J Bauch YW Chen XG Chiou T Fey D Gauvin E Gubbins GC Hsieh KC Marsh KW Mollison M Pong TK Shaughnessy MP Sheets M Smith JM Trevillyan U Warrior CD Wegner GW Carter, J Med Chem 2000 43 16 2975 2981
152. Suppressors of cytokine signaling and immunity. M Kubo T Hanada A Yoshimura, Nat Immunol 2003 4 12 1169 1176
153. Functional polymorphism in the suppressor of cytokine signaling 1 gene associated with adult asthma. M Harada K Nakashima T Hirota M Shimizu S Doi K Fujita T Shirakawa T Enomoto M Yoshikawa H Moriyama K Matsumoto H Saito Y Suzuki Y Nakamura M Tamari, Am J Respir Cell Mol Biol 2007 36 4 491 496
154. Suppressor of cytokine signaling 3 (SOCS3) in Th2 cells evokes Th2 cytokines, IgE, and eosinophilia. M Kubo H Inoue, Curr Allergy Asthma Rep 2006 6 1 32 39
155. SOCS proteins in T helper cell differentiation: implications for allergic disorders? H Inoue M Kubo, Expert Rev Mol Med 2004 6 22 1 11
156. Role of endogenous inhibitors of cytokine signaling in allergic asthma. H Inoue S Fukuyama K Matsumoto M Kubo A Yoshimura, Curr Med Chem 2007 14 2 181 189
157. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Y Seki H Inoue N Nagata K Hayashi S Fukuyama K Matsumoto O Komine S Hamano K Himeno K Inagaki-Ohara N Cacalano A O'Garra T Oshida H Saito JA Johnston A Yoshimura M Kubo, Nat Med 2003 9 8 1047 1054
158. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Y Seki K Hayashi A Matsumoto N Seki J Tsukada J Ransom T Naka T Kishimoto A Yoshimura M Kubo, Proc Natl Acad Sci USA 2002 99 20 13003 13008
159. The control of allergic conjunctivitis by suppressor of cytokine signaling (SOCS) 3 and SOCS-5 in a murine model. A Ozaki Y Seki A Fukushima M Kubo, J Immunol 2005 175 8 5489 5497
160. SOCS-5 is expressed in primary B and T lymphoid cells but is dispensable for lymphocyte production and function. C Brender R Columbus D Metcalf E Handman R Starr N Huntington D Tarlinton N Ødum SE Nicholson NA Nicola DJ Hilton WS Alexander, Mol Cell Biol 2004 24 13 6094 6103
161. Overexpression of suppressor of cytokine signalling-5 augments eosinophilic airway inflammation in mice. M Ohshima A Yokoyama H Ohnishi H Hamada N Kohno J Higaki T Naka, Clin Exp Allergy 2007 37 5 735 742
162. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. H Hammad HJ De Heer T Soullie V Angeli F Trottein HC Hoogsteden BN Lambrecht, Am J Pathol 2004 164 1 263 271
163. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. G Woerly K Honda M Loyens JP Papin J Auwerx B Staels M Capron D Dombrowicz, J Exp Med 2003 198 3 411 421
164. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. A Trifilieff A Bench M Hanley D Bayley E Campbell P Whittaker, Br J Pharmacol 2003 139 1 163 171
165. Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. C Mueller V Weaver JP Vanden Heuvel A August MT Cantorna, Arch Biochem Biophys 2003 418 2 186 196
166. Involvement of IL-10 in peroxisome proliferator-activated receptor gamma-mediated anti-inflammatory response in asthma. SR Kim KS Lee HS Park SJ Park KH Min SM Jin YC Lee, Mol Pharmacol 2005 68 6 1568 1575
167. Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. K Honda P Marquillies M Capron D Dombrowicz, J Allergy Clin Immunol 2004 113 5 882 888
168. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. KS Lee SJ Park PH Hwang HK Yi CH Song OH Chai JS Kim MK Lee YC Lee, FASEB J 2005 19 8 1033 1035
169. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma. KS Lee SJ Park SR Kim KH Min SM Jin HK Lee YC Lee, J Immunol 2006 177 8 5248 5257
170. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. KS Lee SR Kim SJ Park HS Park KH Min SM Jin MK Lee UH Kim YC Lee, J Allergy Clin Immunol 2006 118 1 120 127
171. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. M Spears C McSharry NC Thomson, Clin Exp Allergy 2006 36 12 1494 1504
172. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. MG Belvisi DJ Hele MA Birrell, Eur J Pharmacol 2006 533 1-3 101 109
173. Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma. S Khanna ME Sobria PV Bharatam, J Med Chem 2005 48 8 3015 3025
174. Procaterol upregulates peroxisome proliferator-activated receptor-gamma expression in human eosinophils. S Ueki A Usami H Oyamada N Saito T Chiba G Mahemuti W Ito H Kato H Kayaba J Chihara, Int Arch Allergy Immunol 2006 140 suppl 1 S35 41
175. Theophylline and dexamethasone induce peroxisome proliferator-activated receptor-gamma expression in human eosinophils. A Usami S Ueki W Ito Y Kobayashi T Chiba G Mahemuti H Oyamada Y Kamada M Fujita H Kato N Saito H Kayaba J Chihara, Pharmacology 2006 77 1 33 37
176. Kinase targets and inhibitors for the treatment of airway inflammatory diseases: the next generation of drugs for severe asthma and COPD? IM Adcock G Caramori, Biodrugs 2004 18 3 167 180
177. p38 alpha mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T cells and Th2 effector cells. PH Schafer SA Wadsworth L Wang SJ Siekierka, J Immunol 1999 162 2 7110 7119
178. Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. W Duan JH Chan K McKay JR Crosby HH Choo BP Leung JG Karras WS Wong, Am J Respir Crit Care Med 2005 171 6 571 578
179. Targeting mitogen-activated protein kinases for asthma. W Duan WS Wong, Curr Drug Targets 2006 7 6 691 698
180. Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. SJ Lane IM Adcock D Richards C Hawrylowicz PJ Barnes TH Lee, J Clin Invest 1998 102 12 2156 2164
181. A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat. TJ Huang IM Adcock KF Chung, Br J Pharmacol 2001 134 5 1029 1036
182. Glycosaminoglycans and the regulation of allergic inflammation. MJ Rose C Page, Curr Drug Targets Inflamm Allergy 2004 3 3 221 225
183. Eotaxin selectively binds heparin: An interaction that protects eotaxin from proteolysis and potentiates chemotactic activity in vivo. JI Ellyard L Simson K Johnston C Freeman CR Parish, J Biol Chem 2007 282 20 15238 15247
184. In vitro heparan sulfate modulates the immune responses of normal and tumor-bearing mice. RM Rashid JM Lee J Fareed MR Young, Immunol Invest 2007 36 2 183 201
185. Glycosaminoglycans, airways inflammation and bronchial hyperresponsiveness. R Lever C Page, Pulm Pharmacol Ther 2001 14 3 249 254
186. Heparin and related molecules as a new treatment for asthma. Z Diamant CP Page, Pulm Pharmacol Ther 2000 13 1 1 4
187. The role of proteoglycans in the regulation of airways inflammation and airways remodelling. C Page, J Allergy Clin Immunol 2000 105 2 Pt 2 S518 521
188. Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin. T Ahmed J Garrigo I Danta, N Engl J Med 1993 329 2 90 95
189. Prevention of exercise-induced bronchoconstriction by inhaled low-molecular-weight heparin. T Ahmed BJ Gonzales I Danta, Am J Respir Crit Care Med 1999 160 2 576 581
190. Time course of the protective effect of inhaled heparin on exercise-induced asthma. J Garrigo I Danta T Ahmed, Am J Respir Crit Care Med 1996 153 5 1702 1707
191. Cytokine-directed therapies for the treatment of chronic airway diseases. PJ Barnes, Cytokine Growth Factor Rev 2003 14 6 511 522
192. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. SM Grunewald A Werthmann B Schnarr CE Klein EB Brocker M Mohrs F Brombacher W Sebald A Duschl, J Immunol 1998 160 8 4004 4009
193. The IL-4 receptor antagonist (Bay 16-9996) reverses airway hyperresponsiveness in a primate model of asthma. P Harris D Lindell N Fitch R Gundel, Am J Respir Crit Care Med 1999 159 suppl A230
194. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. JW Steinke L Borish, Respir Res 2001 2 2 66 70
195. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. WR Henderson Jr EY Chi CR Maliszewski, J Immunol 2000 164 2 1086 1095
196. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. LC Borish HS Nelson MJ Lanz L Claussen JB Whitmore JM Agosti L Garrison, Am J Respir Crit Care Med 1999 160 6 1816 1823
197. IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. LC Borish HS Nelson J Corren G Bensch WW Busse JB Whitmore JM Agosti, J Allergy Clin Immunol 2001 107 6 963 970
198. Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. JG Karras JR Crosby M Guha D Tung DA Miller WA Gaarde RS Geary BP Monia SA Gregory, Am J Respir Cell Mol Biol 2007 36 3 276 285
199. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Y Ma KT Hayglass AB Becker AJ Halayko S Basu FER Simons Z Peng, Allergy 2007 62 6 675 682
200. Requirement for IL-13 independently of IL-4 in experimental asthma. G Grunig M Warnock AE Wakil R Venkayya F Brombacher DM Rennick D Sheppard M Mohrs DD Donaldson RM Locksley DB Corry, Science 1998 282 5397 2261 2263
201. Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling. G Yang A Volk T Petley E Emmell J Giles-Komar X Shang J Li AM Das D Shealy DE Griswold L Li, Cytokine 2004 28 6 224 232
202. Efficacy of IL-13 neutralization in a sheep model of experimental asthma. MT Kasaian DD Donaldson L Tchistiakova K Marquette XY Tan A Ahmed BA Jacobson A Widom TA Cook X Xu AB Barry SJ Goldman WM Abraham, Am J Respir Cell Mol Biol 2007 36 3 368 376
203. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. S Wenzel D Wilbraham R Fuller EB Getz M Longphre, Lancet 2007 370 9596 1422 1431
204. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). C Blanchard A Mishra H Saito-Akei P Monk I Anderson ME Rothenberg, Clin Exp Allergy 2005 35 8 1096 1103
205. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. G Yang L Li A Volk E Emmell T Petley J Giles-Komar P Rafferty M Lakshminarayanan DE Griswold PJ Bugelski AM Das, J Pharmacol Exp Ther 2005 313 1 8 15
206. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. A Bree FJ Schlerman M Wadanoli L Tchistiakova K Marquette XY Tan BA Jacobson A Widom TA Cook N Wood S Vunnum R Krykbaev X Xu DD Donladson SJ Goldman J Sypek MT Kasain, J Allergy Clin Immunol 2007 119 5 1251 1257
207. Novel Recombinant IL-13 Peptide-based Vaccine Reduces Airway Allergic Inflammatory Responses in Mice. Y Ma KT Hayglass AB Becker Y Fan X Yang S Basu G Srinivasan FE Simons AJ Halayko Z Peng, Am J Respir Crit Care Med 2007 176 5 439 445
208. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. JC Kips BJ O'Connor SJ Langley A Woodcock HA Kerstjens DS Postma M Danzig F Cuss RA Pauwels, Am J Respir Crit Care Med 2003 167 12 1655 1659 Comment in: Am J Respir Crit Care Med 2003, 167 (12):1586-1587
209. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. PT Flood-Page AN Menzies-Gow AB Kay DS Robinson, Am J Respir Crit Care Med 2003 167 2 199 204 Comment in: Am J Respir Crit Care Med 2003, 167 (2):102-103
210. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. C Buttner A Lun T Splettstoesser G Kunkel H Renz, Eur Respir J 2003 21 5 799 803
211. Effect of interleukin-5 receptor-alpha short hairpin RNA-expressing vector on bone marrow eosinophilopoiesis in asthmatic mice. H Mao FO Wen CT Liu ZA Liang ZL Wang KS Yin, Adv Ther 2006 23 6 938 956
212. A preliminary study towards downregulation of murine bone marrow eosinophilopoiesis mediated by small molecule inhibition of interleukin-5 receptor alpha gene in vitro. H Mao FO Wen SY Li ZA Liang CT Liu KS Yin ZL Wang, Respiration 2007 74 3 320 328
213. Gp130 and the interleukin-6 family of cytokines. T Taga T Kishimoto, Annu Rev Immunol 1997 15 797 819
214. The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. A Doganci T Eigenbrod N Krug GT De Sanctis M Hausding VJ Erpenbeck el-B Haddad HA Lehr E Schmitt T Bopp KJ Kallen U Herz S Schmitt C Luft O Hecht JM Hohlfeld H Ito N Nishimoto K Yoshikazi T Kishimoto S Rose-John H Renz MF Neurath PR Galle S Finotto, J Clin Invest 2005 115 2 313 325
215. Interleukin-9 as a possible therapeutic target in both asthma and chronic obstructive airways disease. PS McNamara RL Smyth, Drug News Perspect 2005 18 10 615 621
216. IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. V Steenwinckel J Louahed C Orabona F Huax G Warnier A McKenzie D Lison R Levitt JC Renauld, J Immunol 2007 178 5 3244 3251
217. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. A Shimbara P Christodoulopoulos A Soussi-Gounni R Olivenstein Y Nakamura RC Levitt NC Nicolaides KJ Holroyd A Tsicopoulos JJ Lafitte B Wallaert QA Hamid, J Allergy Clin Immunol 2000 105 1 Pt 1 108 115
218. Elevated expression of interleukin-9 mRNA in the bronchial mucosa of atopic asthmatics and allergen-induced cutaneous late-phase reaction: relationships to eosinophils, mast cells and T lymphocytes. S Ying Q Meng AB Kay DS Robinson, Clin Exp Allergy 2002 32 6 866 871
219. Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes. VJ Erpenbeck JM Hohlfeld B Volkmann A Hagenberg H Geldmacher A Braun N Krug, J Allergy Clin Immunol 2003 111 6 1319 1327
220. Pro-fibrotic Effect of IL-9 Overexpression in a Model of Airway Remodeling. S van den Brule J Heymans X Havaux JC Renauld D Lison F Huax O Denis, Am J Respir Cell Mol Biol 2007 37 2 202 209
221. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. PG Fallon HE Jolin P Smith CL Emson MJ Townsend R Fallon P Smith AN McKenzie, Immunity 2002 17 1 7 17
222. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. JM Townsend GP Fallon JD Matthews P Smith EH Jolin NA McKenzie, Immunity 2000 13 4 573 583
223. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. G Cheng M Arima K Honda H Hirata F Eda N Yoshida F Fukushima Y Ishii T Fukuda, Am J Respir Crit Care Med 2002 166 3 409 416
224. Effect of anti-mIL-9 antibody on the development of pulmonary inflammation and airway hyperresponsiveness in allergic mice. TT Kung B Luo Y Crawley CG Garlisi K Devito M Minnicozzi RW Egan W Kreutner RW Chapman, Am J Respir Cell Mol Biol 2001 25 5 600 605
225. Airway allergen exposure stimulates bone marrow eosinophilia partly via IL-9. B Sitkauskiene M Radinger A Bossios AK Johansson R Sakalauskas J Lotvall, Respir Res 2005 6 33
226. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. CG Lee RJ Homer L Cohn H Link S Jung JE Craft BS Graham TR Johnson JA Elias, J Biol Chem 2002 277 38 35466 35474
227. Attenuated production of intracellular IL-10 and IL-12 in monocytes from patients with severe asthma. K Tomita S Lim T Hanazawa O Usmani R Stirling KF Chung PJ Barnes IM Adcock, Clin Immunol 2002 102 3 258 266
228. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. E Xystrakis S Kusumakar S Boswell E Peek Z Urry DF Richards T Adikibi C Pridgeon M Dallman TK Loke DS Robinson FJ Barrat A O'Garra P Lavender TH Lee C Corrigan CM Hawrylowicz, J Clin Invest 2006 116 1 146 155
229. Haplotype associated with low interleukin-10 production in patients with severe asthma. S Lim E Crawley P Woo PJ Barnes, Lancet 1998 352 9122 113
230. Adenoviral interleukin-12 gene transduction into human bronchial epithelial cells: up-regulation of pro-inflammatory cytokines and its prevention by corticosteroids. H Ogawa N Nishimura Y Nishioka M Azuma H Yanagawa S Sone, Clin Exp Allergy 2003 33 7 921 929
231. Effects of recombinant human interleukin-12 on eosinophils, airway hyperresponsiveness, and the late asthmatic response. SA Bryan BJ O'Connor S Matti MJ Leckie V Kanabar J Khan SJ Warrington L Renzetti A Rames JA Bock MJ Boyce TT Hansel ST Holgate PJ Barnes, Lancet 2000 356 9248 2149 2153
232. Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity. H Matsuse X Kong J Hu SF Wolf RF Lockey SS Mohapatra, Int Immunopharmacol 2003 3 4 457 468
233. Family based association analysis of the IL2 and IL15 genes in allergic disorders. U Christensen A Haagerup HG Binderup J Vestbo TA Kruse AD Borgium, Eur J Hum Genet 2006 14 2 227 235
234. Multilocus haplotype analyses reveal association between 5 novel IL-15 polymorphisms and asthma. T Kurz K Strauch H Dietrich S Braun S Hierl SP Jerkic TF Wienker KA Deichmann A Heinzmann, J Allergy Clin Immunol 2004 113 5 896 901
235. Expression of IL-15 in inflammatory pulmonary diseases. S Muro R Taha A Tsicopoulos R Olivenstein AB Tonnel P Christodoulopoulos B Wallaert Q Hamid, J Allergy Clin Immunol 2001 108 6 970 975
236. Overexpression of IL-15 in vivo enhances Tc1 response, which inhibits allergic inflammation in a murine model of asthma. R Ishimitsu H Nishimura T Yajima T Watase H Kawauchi Y Yoshikai, J Immunol 2001 166 3 1991 2001
237. Blocking IL-15 prevents the induction of allergen-specific T cells and allergic inflammation in vivo. R Ruckert K Brandt A Braun HG Hoymann U Herz V Budagian H Durkop H Renz S Bulfone-Paus, J Immunol 2005 174 9 5507 5515
238. Involvement of human natural killer cells in asthma pathogenesis: natural killer 2 cells in type 2 cytokine predominance. H Wei J Zhang W Xiao J Feng R Sun Z Tian, J Allergy Clin Immunol 2005 115 4 841 847
239. Fluticasone induces T cell apoptosis in the bronchial wall of mild to moderate asthmatics. S O'sullivan L Cormican CM Burke LW Poulter, Thorax 2004 59 8 657 661
240. Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions. M Bombardieri IB McInnes C Pitzalis, Expert Opin Biol Ther 2007 7 1 31 40
241. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. HT Maecker G Hansen DM Walter RH DeKruyff S Levy DT Umetsu, J Immunol 2001 166 2 959 965
242. Induction of allergic inflammation by interleukin-18 in experimental animal models. H Tsutsui T Yoshimoto N Hayashi H Mizutani K Nakanishi, Immunol Rev 2004 202 115 138
243. Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse. T Sugimoto Y Ishikawa T Yoshimoto N Hayashi J Fujimoto K Nakanishi, J Exp Med 2004 199 4 535 545
244. Interleukin-18 enhances antigen-induced eosinophil recruitment into the mouse airways. K Kumano A Nakao H Nakajima F Hayashi M Kurimoto H Okamura Y Saito I Iwamoto, Am J Respir Crit Care Med 1999 160 3 873 878
245. IFN-gamma-inducing factor (IL-18) increases allergic sensitization, serum IgE, Th2 cytokines, and airway eosinophilia in a mouse model of allergic asthma. JS Wild A Sigounas N Sur MS Siddiqui R Alam M Kurimoto S Sur, J Immunol 2000 164 5 2701 2710
246. Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-gamma, IL-4, IL-10 and IL-13) in patients with allergic asthma. CK Wong CY Ho FW Ko CH Chan AS Ho DS Hui CW Lam, Clin Exp Immunol 2001 125 2 177 183
247. IL-18 might reflect disease activity in mild and moderate asthma exacerbation. H Tanaka N Miyazaki K Oashi S Teramoto M Shiratori M Hashimoto M Ohmichi S Abe, J Allergy Clin Immunol 2001 107 2 331 336
248. Reduced interleukin-18 levels in BAL specimens from patients with asthma compared to patients with sarcoidosis and healthy control subjects. LP Ho M Davis A Denison FT Wood AP Greening, Chest 2002 121 5 1421 1426
249. Interleukin-18 levels in induced sputum are reduced in asthmatic and normal smokers. A McKay M Komai-Koma KJ MacLeod CC Campbell SM Kitson R Chaudhuri L Thomson C McSharry FY Liew NC Thomson, Clin Exp Allergy 2004 34 6 904 910
250. IL-28, IL-29 and their class II cytokine receptor IL-28R. P Sheppard W Kindsvogel W Xu K Henderson S Schlutsmeyer TE Whitmore R Kuestner U Garrigues C Birks J Roraback C Ostrander D Dong J Shin S Presnell B Fox B Haldeman E Cooper D Taft T Gilbert FJ Grant M Tackett W Krivan G McKnight C Clegg D Foster KM Klucher, Nat Immunol 2003 4 1 63 68
251. The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions. JA Langer EC Cutrone S Kotenko, Cytokine Growth Factor Rev 2004 15 1 33 48
252. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. L Dumoutier C Leemans D Lejeune SV Kotenko JC Renauld, J Immunol 2001 167 7 3545 3549
253. Full house: 12 receptors for 27 cytokines. SV Kotenko JA Langer, Int Immunopharmacol 2004 4 5 593 608
254. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. RP Donnelly F Sheikh SV Kotenko H Dickensheets, J Leukoc Biol 2004 76 2 314 321
255. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. CD Krause S Pestka, Pharmacol Ther 2005 106 3 299 346
256. IL-28 and IL-29: newcomers to the interferon family. G Uze D Monneron, Biochimie 2007 89 6-7 729 734
257. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. G Gallagher J Eskdale W Jordan J Peat J Campbell M Boniotto GP Lennon H Dickensheets RP Donnelly, Int Immunopharmacol 2004 4 5 615 626
258. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). G Gallagher H Dickensheets J Eskdale LS Izotova OV Mirochnitchenko JD Peat N Vazquez S Pestka RP Donnelly SV Kotenko, Genes Immun 2000 1 7 442 450
259. IL-19 induces production of IL-6 and TNF-α and results in cell apoptosis through TNF-α YC Liao WG Liang FW Chen JH Hsu MJJ Yang S Chang, J Immunol 2002 169 8 4288 4297
260. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. SC Liao YC Cheng YC Wang CW Wang SM Yang CK Yu CC Shieh KC Cheng MF Lee SR Chiang JM Shieh MS Chang, J Immunol 2004 173 11 6712 6718
261. A2B adenosine receptors induce IL-19 from bronchial epithelial cells, resulting in TNF-alpha increase. H Zhong Y Wu L Belardinelli D Zeng, Am J Respir Cell Mol Biol 2006 35 5 587 592
262. Interleukin-21 is a T-helper cytokine that regulates humoral immunity and cell-mediated anti-tumour responses. PV Sivakumar DC Foster CH Clegg, Immunology 2004 112 2 177 182
263. IL-21: a novel IL-2-family lymphokine that modulates B, T, and natural killer cell responses. T Habib A Nelson K Kaushansky, J Allergy Clin Immunol 2003 112 6 1033 1045
264. A critical role for IL-21 in regulating immunoglobulin production. KR Ozaki CG Spolski CG Feng CF Qi J Cheng A Sher HC Morse 3rd C Liu PL Schwartzberg WJ Leonard, Science 2002 298 5598 1630 1634
265. IgE isotype switch and IgE production are enhanced in IL-21-deficient but not IFN-gamma-deficient mice in a Th2-biased response. XZ Shang KY Ma J Radewonuk J Li XY Song DE Griswold E Emmell T Li, Cell Immunol 2006 241 2 66 74
266. IL-21 limits NK cell responses and promotes antigen-specific T cell activation: a mediator of the transition from innate to adaptive immunity. MT Kasaian MJ Whitters LL Carter LD Lowe JM Jussif B Deng KA Johnson JS Witek M Senices RF Konz AL Wurster DD Donaldson M Collins DA Young MJ Grusby, Immunity 2002 16 4 559 569
267. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. BD Curti, Expert Rev Anticancer Ther 2006 6 6 905 909
268. Role of interleukin-21 in inflammation and allergy. D Fina MC Fantini F Pallone G Monteleone, Inflamm Allergy Drug Targets 2007 6 1 63 68
269. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. K Wolk R Sabat, Cytokine Growth Factor Rev 2006 17 5 367 380
270. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. HB Oral SV Kotenko M Yilmaz O Mani J Zumkehr K Blaser CA Akdis M Akdis, Eur J Immunol 2006 36 2 380 388
271. Interleukin-22: a potential immunomodulatory molecule in the lung. HA Whittington L Armstrong KM Uppington AB Millar, Am J Respir Cell Mol Biol 2004 31 2 220 226
272. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. G Trinchieri S Pflanz RA Kastelein, Immunity 2003 19 5 641 644
273. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. B Oppmann R Lesley B Blom JC Timans Y Xu B Hunte F Vega N Yu J Wang K Singh F Zonin E Vaisberg T Churakova M Liu D Gorman J Wagner S Zurawski Y Liu JS Abrams KW Moore D Rennick R de Waal-Malefyt C Hannum JF Bazan RA Kastelein, Immunity 2000 13 5 715 725
274. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. CL Langrish Y Chen WM Blumenschein J Mattson B Basham JD Sedgwick T McClanahan RA Kastelein DJ Cua, J Exp Med 2005 201 2 233 240
275. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. H Park Z Li XO Yang SH Chang R Nurieva YH Wang Y Wang L Hood Z Zhu Q Tian C Dong, Nat Immunol 2005 6 11 1133 1141
276. Interleukin 25 in allergic airway inflammation. T Tamachi Y Maezawa K Ikeda I Iwamoto H Nakajima, Int Arch Allergy Immunol 2006 140 suppl 1 59 62
277. IL-27, a heterodimeric cytokine composed of EBIS and p28 protein, induces proliferation of naïve CD4(+) T cells. S Pflanz JC Timans J Cheung R Rosales H Kanzler J Gilbert L Hibbert T Churakova M Travis E Vaisberg WM Blumenschein JD Mattson JL Wagner W To S Zurawski TK McClanahan DM Gorman JF Bazan R de Waal Malefyt D Rennick RA Kastelein, Immunity 2002 16 6 779 790
278. Identification of polymorphisms in human interleukin-27 and their association with asthma in a Korean population. SC Chae CS Li JW Kim JY Yang O Zhang YC Lee YS Yang HT Chung, J Hum Genet 2007 52 4 355 361
279. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. S Pflanz L Hibbert J Mattson R Rosales E Vaisberg JF Bazan JH Phillips TK McClanahan R de Waal Malefyt RA Kastelein, J Immunol 2004 172 4 2225 2231
280. + T cells partially through STAT3-dependent mechanism. T Yoshimura A Takeda S Hamano Y Miyazaki I Kinjyo T Ishibashi A Yoshimura H Yoshida, J Immunol 2006 177 8 5377 5385
281. Regulation of Defense Responses against Protozoan Infection by Interleukin-27 and Related Cytokines. H Yoshida Y Miyazaki S Wang S Hamano, J Biomed Biotechnol 2007 2007 3 79401
282. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. C Neufert C Becker S Wirtz MC Fantini B Weigmann PR Galle MF Neurath, Eur J Immunol 2007 37 7 1809 1816
283. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. JS Stumhofer A Laurence EH Wilson E Huang CM Tato LM Johnson AV Villarino Q Huang A Yoshimura D Sehy CJ Saris JJ O'Shea L Hennighausen M Ernst CA Hunter, Nat Immunol 2006 7 9 937 945
284. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. S Lucas N Ghilardi J Li FJ de Sauvage, Proc Natl Acad Sci USA 2003 100 25 15047 15052
285. 3. Cytokines and chemokines. JW Steinke L Borish, J Allergy Clin Immunol 2006 117 2 Suppl Mini-Primer S441 445
286. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. Y Miyazaki H Inoue M Matsumura K Matsumoto T Nakano M Tsuda S Hamano A Yoshimura H Yoshida, J Immunol 2005 175 4 2401 2407
287. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. SR Dillon C Sprecher A Hammond J Bilsborough M Rosenfeld-Franklin SR Presnell HS Haugen M Maurer B Harder J Johnston S Bort S Mudri JL Kuijper T Bukowski P Shea DL Dong M Dasovich FJ Grant L Lockwood SD Levin C LeCiel K Waggie H Day S Topouzis J Kramer R Kuestner Z Chen D Foster J Parrish-Novak JA Gross, Nat Immunol 2004 5 7 752 760
288. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. C Diveu AH Lak-Hal J Froger E Ravon L Grimaud F Barbier J Hermann H Gascan S Chevalier, Eur Cytokine Netw 2004 15 4 291 302
289. Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. S Chattopadhyay E Tracy P Liang O Robledo S Rose-John H Baumann, J Biol Chem 2007 282 5 3014 3026
290. Complete overlap of interleukin-31 receptor A and oncostatin M receptor beta in the adult dorsal root ganglia with distinct developmental expression patterns. T Bando Y Morikawa T Komori E Senba, Neuroscience 2006 142 4 1263 1271
291. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J Bilsborough DY Leung M Maurer M Howell M Boguniewicz L Yao H Storey C LeCiel B Harder JA Gross, J Allergy Clin Immunol 2006 117 2 418 425
292. IL-31: a new link between T cells and pruritus in atopic skin inflammation. E Sonkoly A Muller AI Lauerma A Pivarcsi H Soto L Kemeny H Alenius MC Dieu-Nosjean S Meller J Rieker M Steinhoff TK Hoffmann T Ruzicka A Zlotnik B Homey, J Allergy Clin Immunol 2006 117 2 411 417
293. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. MM Neis B Peters A Dreuw J Wenzel T Bieber C Mauch T Krieg S Stanzel PC Heinrich HF Merk A Bosio JM Baron HM Hermanns, J Allergy Clin Immunol 2006 118 4 930 937
294. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. JG Perrigoue J Li C Zaph M Goldschmidt P Scott FJ de Sauvage EJ Pearce N Ghilardi D Artis, J Exp Med 2007 204 3 481 487
295. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. J Schmitz A Owyang E Oldham Y Song E Murphy TK LcClanahan G Zurawski M Moshrefi J Oin X Li DM Gorman JF Bazan RA Kastelein, Immunity 2005 23 5 479 490
296. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. V Carriere L Roussel N Ortega DA Lacorre L Americh L Aguilar G Bouche JP Girard, Proc Natl Acad Sci USA 2007 104 1 282 287
297. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. D Xu WL Chan BP Leung Fp Huang R Wheeler D Piedrafita JH Robinson FY Liew, J Exp Med 1998 187 5 787 794
298. Regulation and function of T1/ST2 expression on CD4+ T cells: induction of type 2 cytokine production by T1/ST2 cross-linking. C Meisel K Bonhagen M Lohning AJ Coyle JC Gutierrez-Ramos A Radbruch T Kamradt, J Immunol 2001 166 5 3143 3150
299. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. AJ Coyle C Lloyd J Tian T Nguyen C Erikkson L Wang P Ottoson P Persson T Delaney S Lehar S Lin L Poisson C Meisel T Kamradt T Bjerke D Levinson JC Gutierrez-Ramos, J Exp Med 1999 190 7 895 902
300. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. K Hoshino S Kashiwamura K Kuribayashi T Kodama T Tsujimura K Nakanishi T Matsuyama K Takeda S Akira, J Exp Med 1999 190 10 1541 1548
301. T1-deficient and T1-Fc-transgenic mice develop a normal protective Th2-type immune response following infection with Nippostrongylus brasiliensis. KA Senn KD McCoy KJ Maloy G Stark E Fröhli T Rülicke R Klemenz, Eur J Immunol 2000 30 7 1929 1938
302. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. JM Townsend GP Fallon JD Matthews EH Jolin AN McKenzie, J Exp Med 2000 191 6 1069 1076
303. ST2: marker, activator and regulator of Th2 immunity? RK Kumar PS Foster, Clin Exp Allergy 2002 32 10 1394 1396
304. Granulocyte macrophage colony-stimulating factor-driven respiratory mucosal sensitization induces Th2 differentiation and function independently of interleukin-4. SA Ritz MJ Cundall BU Gajewska D Alvarez JC Gutierrez-Ramos AJ Coyle AN McKenzie MR Stämpfli M Jordana, Am J Respir Cell Mol Biol 2002 27 4 428 435
305. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. EK Brint D Xu H Liu A Dunne AN McKenzie LA O'Neill FY Liew, Nat Immunol 2004 5 4 373 379
306. Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2. A role for Jun N-terminal kinase in IL-4 induction. EK Brint KA Fitzgerald P Smith AJ Coyle JC Gutierrez-Ramos PG Fallon LA O'Neill, J Biol Chem 2002 277 51 49205 49211
307. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. K Oshikawa K Kuroiwa K Tago H Iwahana K Yanagisawa S Ohno S Tominaga Y Sugiyama, Am J Respir Crit Care Med 2001 164 2 277 281
308. Expression and function of the ST2 gene in a murine model of allergic airway inflammation. K Oshikawa K Yanagisawa S Tominaga Y Sugiyama, Clin Exp Allergy 2002 32 10 1520 1526
309. Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling. JR Johnson RE Wiley R Fattouh FK Swirski BU Gajewska AJ Coyle JC Gutierrez-Ramos R Ellis MD Inman M Jordana, Am J Respir Crit Care Med 2004 169 3 378 385
310. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. G Walzl S Matthews S Kendall JC Gutierrez-Ramos AJ Coyle PJ Openshaw T Hussell, J Exp Med 2001 193 7 785 792
311. Surfactant protein D inhibits early airway response in Aspergillus fumigatus-sensitized mice. VJ Erpenbeck M Ziegert D Cavalet-Blanco C Martin R Baelder T Glaab A Braun W Steinhilber B Luettig S Uhlig N Hoymann HG Krug JM Hohlfeld, Clin Exp Allergy 2006 36 7 930 940
312. Therapeutic effect of surfactant protein D in allergic inflammation of mite-sensitized mice. CF Liu YL Chen CC Shieh CK Yu KB Reid JY Wang, Clin Exp Allergy 2005 35 4 515 521
313. Protective roles of pulmonary surfactant proteins, SP-A and SP-D, against lung allergy and infection caused by Aspergillus fumigatus. U Kishore T Madan PU Sarma M Singh BC Urban KB Reid, Immunobiology 2002 205 4-5 610 618
314. Natural porcine surfactant augments airway inflammation after allergen challenge in patients with asthma. VJ Erpenbeck A Hagenberg Y Dulkys J Elsner R Balder H Krentel M Discher A Braun N Krug JM Hohlfeld, Am J Respir Crit Care Med 2004 169 5 578 586
315. Asthma and current intestinal parasite infection: systematic review and meta-analysis. J Leonardi-Bee D Pritchard J Britton, Am J Respir Crit Care Med 2006 174 5 514 523
316. Helminth-derived products inhibit the development of allergic responses in mice. CM Trujillo-Vargas M Werner-Klein G Wohlleben T Polte G Hansen S Ehlers KJ Erb, Am J Respir Crit Care Med 2007 175 4 336 344
317. Proteins secreted by the parasitic nematode Nippostrongylus brasiliensis act as adjuvants for Th2 responses. MJ Holland YM Harcus PL Riches RM Maizels, Eur J Immunol 2000 30 7 1977 1987
318. Helminths, allergic disorders and IgE-mediated immune responses: Where do we stand? KJ Erb, Eur J Immunol 2007 37 5 1170 1173
319. Identification and characterization of a novel antigen from the nematode Nippostrongylus brasiliensis recognized by specific IgE. V Pochanke S Koller R Dayer S Hatak B Ludewig RM Zinkernagel H Hengartner KD McCoy, Eur J Immunol 2007 37 5 1275 1284
320. Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study. S Scrivener H Yemaneberhan M Zebenigus D Tilahun S Girma S Ali P McElroy A Custovic A Woodcock D Pritchard A Venn J Britton, Lancet 2001 358 9292 1493 1499
321. Dose-ranging study for trials of therapeutic infection with Necator americanus in humans. K Mortimer A Brown J Feary C Jagger S Lewis M Antoniak D Pritchard J Britton, Am J Trop Med Hyg 2006 75 5 914 920
322. Parasite role reversal: worms on trial. FH Falcone D Pritchard, Trends Parasitol 2005 21 4 157 160
323. Necatoriasis: treatment and developmental therapeutics. VS Georgiev, Expert Opin Investig Drugs 2000 9 5 1065 1078
324. Ascariasis and hookworm. PS Sarinas RK Chitkara, Semin Respir Infect 1997 12 2 130 137
325. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. J Croese J O'Neil J Masson S Cooke W Melrose D Pritchard R Speare, Gut 2006 55 1 136 137
326. Strategies for targeting T-cells in allergic diseases and asthma. IH Heijink AJ van Oosterhout, Pharmacol Ther 2006 112 2 489 500